NAD+ Boosters (NMN, NR): The Longevity Hype vs. Human Data

NAD+ biology and aging {#nad-biology-and-aging}

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell. It shuttles electrons in energy metabolism and serves as a substrate for enzymes involved in DNA repair and cellular stress responses, including sirtuins and PARP enzymes. Interest in NAD+ as a longevity target rests on a reproducible observation: NAD+ levels decline with age in multiple tissues, in animals and — with less complete data — in humans.

That decline has made NAD+ precursors commercially attractive. The two most prominent are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), both intermediates in the salvage pathway by which cells recycle and rebuild NAD+. Oral supplementation with either raises NAD+ levels in blood. Almost everything disputed in this field begins after that sentence.

What the animal data show {#what-the-animal-data-show}

In rodents, restoring NAD+ levels has produced striking results. Studies in aged mice have reported improvements in mitochondrial function, insulin sensitivity, vascular function, and various measures of healthspan after NMN or NR supplementation. These findings are real, published in high-quality journals, and they are the scientific seed of a multi-hundred-million-dollar supplement market.

They are also findings in mice. The history of aging research is littered with interventions that extended rodent healthspan and failed in humans — resveratrol being the most instructive precedent in this exact research space. Mice are short-lived, genetically uniform, housed in controlled conditions, and given doses that do not translate cleanly to human physiology. Animal data justify human trials; they do not substitute for them.

Every longevity claim for NAD+ boosters ultimately rests on mice. The human trials measure a biomarker, not a benefit.

BioMed Abstracts editorial assessment

Nicotinamide riboside: human trials {#nicotinamide-riboside-human-trials}

The first-in-human pharmacokinetic data for NR came from Trammell and colleagues (Nature Communications, 2016), who demonstrated that orally administered NR is bioavailable in humans and raises blood NAD+ in a dose-dependent manner. This established the fundamental premise: the supplement does what it says on the most basic level — it gets in, and the biomarker moves.

Chronic dosing studies followed. Martens and colleagues (Nature Communications, 2018) gave healthy middle-aged and older adults 1,000 milligrams of NR daily for six weeks. Supplementation was well tolerated, NAD+ levels rose significantly, and an exploratory analysis hinted at lower blood pressure in a subgroup with elevated baseline readings — a signal the authors themselves framed as hypothesis-generating, requiring confirmation in a trial designed for that endpoint.

What NR trials have not shown is equally important. Studies in people with obesity or metabolic dysfunction have generally failed to demonstrate improvements in insulin sensitivity, body composition, or other hard metabolic endpoints. The consistent pattern across the NR literature: NAD+ rises reliably; clinical benefits do not.

NMN: the Yoshino trial and beyond {#nmn-the-yoshino-trial-and-beyond}

The most closely watched NMN trial to date is Yoshino and colleagues (Science, 2021). Twenty-five postmenopausal women with prediabetes who were overweight or obese received 250 milligrams of NMN or placebo daily for ten weeks. The NMN group showed improved muscle insulin sensitivity and enhanced insulin signaling in skeletal muscle — a mechanistically coherent result, and a genuine human finding.

The context matters, though. Twenty-five participants is a small trial. Ten weeks is a short trial. The improvements were confined to muscle insulin sensitivity and signaling; the trial found no significant effects on body weight, body composition, fasting glucose, or a range of other metabolic measures. It is a proof of biological activity in humans, not evidence of clinical benefit — and it has not yet been replicated at scale in an independent, larger trial.

Regulatory status {#regulatory-status}

NMN occupies an unusual regulatory position in the United States. In 2022, the Food and Drug Administration stated that NMN is excluded from the legal definition of a dietary supplement, citing the “drug exclusion” provision: because NMN had been authorized for investigation as a new drug, with substantial clinical investigations instituted and made public before it was marketed as a supplement, the agency takes the position that it may not be lawfully sold as a dietary supplement. Industry groups have challenged this interpretation, and the situation remains contested.

The practical consequence for readers is uncertainty. The regulatory status of NMN products on the US market is unresolved, quality control across manufacturers is not guaranteed by drug-level oversight, and neither NMN nor NR is approved by the FDA to treat, prevent, or slow any disease — including aging. Anyone considering these compounds, particularly alongside existing medication or chronic conditions, should discuss it with a physician.

The bottom line {#the-bottom-line}

The NAD+ booster field delivers exactly one robust human result: the biomarker moves. NR and NMN reliably raise NAD+ levels in blood, and short-term safety at studied doses looks acceptable. Beyond that, the human evidence thins out quickly — one small positive NMN trial on muscle insulin sensitivity, an exploratory blood-pressure signal with NR, and a string of null results on metabolic endpoints.

Nothing in the human literature currently supports claims about lifespan, rejuvenation, or disease prevention, and the regulatory ground under NMN in particular is unstable. The biology remains genuinely interesting, and larger trials are underway. Until they report, NAD+ boosters are an expensive way to change a lab value, not a demonstrated way to change a health outcome.